ANI Pharmaceuticals (ANIP) vs Xencor (XNCR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Xencor (XNCR) has outperformed ANI Pharmaceuticals (ANIP) over the past year, gaining 97.6% versus a loss of 18.6%. Over five years, ANIP leads with a +91.7% price change compared with -36.3% for XNCR. Xencor is the larger company by market cap ($1.83 billion vs $1.70 billion), about 1.1 times the size, while ANI Pharmaceuticals is growing revenue faster (+43.8% vs +13.7%).
ANI Pharmaceuticals converts more of its revenue into profit, with a net margin of 8.9% versus -73.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANIP | XNCR |
|---|---|---|
| Share price | $73.89 | $24.63 |
| Market cap | $1.70B | $1.83B |
| 1-day change | +2.65% | +0.53% |
| YTD return | -6.40% | +60.03% |
| 1-year return | -18.61% | +97.58% |
| 5-year return | +91.72% | -36.31% |
| P/E ratio (TTM) | 15.99 | — |
| Forward P/E | 7.27 | — |
| EPS (TTM) | $4.62 | $-2.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $883.37M | $125.58M |
| Revenue growth (YoY) | +43.78% | +13.65% |
| Net income (latest FY) | $78.34M | $-91.92M |
| Gross margin | 61.36% | — |
| Operating margin | 12.58% | -141.35% |
| Net margin | 8.87% | -73.20% |
| 52-week high | $97.00 | $30.61 |
| 52-week low | $69.58 | $10.38 |
| Distance from 52-week high | -23.82% | -19.54% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +43.16% | +27.57% |
| Average volume | 376.38K | 1.32M |
| Shares outstanding | 22.96M | 74.35M |
| Employees | 970 | 260 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- XNCR has outperformed ANIP by 116.2 percentage points over the past year.
- ANI Pharmaceuticals is more profitable, keeping 8.9 cents of every revenue dollar as net income versus -73.2 cents for Xencor.
- ANI Pharmaceuticals grew revenue faster in its latest fiscal year (+43.78% vs +13.65%).
About ANI Pharmaceuticals
ANIP stock →ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products.
Health Care · Biotechnology: Pharmaceutical Preparations · 970 employees
About Xencor
XNCR stock →Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 260 employees
ANIP vs XNCR FAQ
Which is bigger, ANI Pharmaceuticals or Xencor?
Xencor (XNCR) is larger, with a market capitalization of $1.83B compared with $1.70B for ANI Pharmaceuticals (ANIP).
Which stock has performed better over the past year, ANIP or XNCR?
XNCR returned +97.58% over the past 12 months, compared with -18.61% for ANIP (price return, excluding dividends). Past performance does not predict future results.
Are ANI Pharmaceuticals and Xencor in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.